
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
Brussels-Lack of intellectual property protection is not causing the erosion of European pharma, reports the European Generics Association.
over 25 years ago
Decision Making at Digital Speedover 25 years ago
Mergers: Big Pharma Shrinks Someover 25 years ago
Grace Under Fireover 25 years ago
Get Ready to Merge or Divergeover 25 years ago
Pharma's Quantum Shuffleover 25 years ago
Science-Driven Marketing





